Shattuck Labs, Inc. (STTK)

NMS – Цена в реальном времени. Валюта: USD

6.44

+0.53 (8.97%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

6.48

+0.04 (0.62%)

После закрытия: Jun 26, 2026, 7:20 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Shattuck Labs, Inc. (STTK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Shattuck Labs, Inc. (STTK)

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript

Why Is Shattuck Labs Stock Trading Lower On Monday?

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Видео

No Data

Пресс-релизы

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

Shattuck Labs Announces Phase 1 Results for SL-325

Search stocks

Shattuck Labs, Inc. (STTK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Shattuck Labs, Inc. (STTK)

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript

Why Is Shattuck Labs Stock Trading Lower On Monday?

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Видео

No Data

Пресс-релизы

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

Shattuck Labs Announces Phase 1 Results for SL-325